RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celldex Therapeutics Stock

Celldex Therapeutics EBIT 2024

Celldex Therapeutics EBIT

-185.31 M USD

Ticker

CLDX

ISIN

US15117B2025

WKN

A2PEAB

In 2024, Celldex Therapeutics's EBIT was -185.31 M USD, a 30.46% increase from the -142.04 M USD EBIT recorded in the previous year.

The Celldex Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e40.65
2027e-255.59
2026e-305.99
2025e-229.71
2024e-185.31
2023-142.04
2022-100.23
2021-67.74
2020-45.35
2019-53.23
2018-46.79
2017-108.53
2016-132.92
2015-129.54
2014-122.43
2013-81.44
2012-58.08
2011-43.4
2010-6.46
2009-37.45
2008-34
2007-15.51
2006-17.62
2005-18.86
2004-13.58

Celldex Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Celldex Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celldex Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celldex Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Celldex Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Celldex Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Celldex Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celldex Therapeutics’s growth potential.

Celldex Therapeutics Revenue, EBIT and net profit per share

DateCelldex Therapeutics RevenueCelldex Therapeutics EBITCelldex Therapeutics Net Income
2029e870.14 M undefined0 undefined76.41 M undefined
2028e413.61 M undefined40.65 M undefined-123.74 M undefined
2027e60.2 M undefined-255.59 M undefined-247.47 M undefined
2026e3.78 M undefined-305.99 M undefined-238.35 M undefined
2025e3.64 M undefined-229.71 M undefined-198.96 M undefined
2024e4.16 M undefined-185.31 M undefined-166.86 M undefined
20236.88 M undefined-142.04 M undefined-141.43 M undefined
20222.36 M undefined-100.23 M undefined-112.33 M undefined
20214.65 M undefined-67.74 M undefined-70.51 M undefined
20207.42 M undefined-45.35 M undefined-59.78 M undefined
20193.57 M undefined-53.23 M undefined-50.88 M undefined
20189.54 M undefined-46.79 M undefined-151.18 M undefined
201712.74 M undefined-108.53 M undefined-93.03 M undefined
20166.79 M undefined-132.92 M undefined-128.53 M undefined
20155.48 M undefined-129.54 M undefined-127.2 M undefined
20143.59 M undefined-122.43 M undefined-118.08 M undefined
20134.11 M undefined-81.44 M undefined-81.55 M undefined
201211.2 M undefined-58.08 M undefined-59.12 M undefined
20119.27 M undefined-43.4 M undefined-44.8 M undefined
201046.79 M undefined-6.46 M undefined-2.53 M undefined
200915.18 M undefined-37.45 M undefined-36.53 M undefined
20087.46 M undefined-34 M undefined-47.5 M undefined
20071.41 M undefined-15.51 M undefined-15.07 M undefined
2006900,000 undefined-17.62 M undefined-17.83 M undefined
20053.09 M undefined-18.86 M undefined-18.1 M undefined
20046.86 M undefined-13.58 M undefined-13.2 M undefined

Celldex Therapeutics stock margins

The Celldex Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celldex Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celldex Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Celldex Therapeutics's sales revenue. A higher gross margin percentage indicates that the Celldex Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Celldex Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Celldex Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celldex Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celldex Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celldex Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Celldex Therapeutics Margin History

Celldex Therapeutics Gross marginCelldex Therapeutics Profit marginCelldex Therapeutics EBIT marginCelldex Therapeutics Profit margin
2029e100 %0 %8.78 %
2028e100 %9.83 %-29.92 %
2027e100 %-424.56 %-411.09 %
2026e100 %-8,092.86 %-6,303.77 %
2025e100 %-6,303.88 %-5,459.92 %
2024e100 %-4,457.67 %-4,013.97 %
2023100 %-2,063.66 %-2,054.76 %
2022100 %-4,247.03 %-4,759.75 %
2021100 %-1,456.77 %-1,516.34 %
2020100 %-611.19 %-805.66 %
2019100 %-1,491.04 %-1,425.21 %
2018100 %-490.46 %-1,584.7 %
2017100 %-851.88 %-730.22 %
2016100 %-1,957.58 %-1,892.93 %
2015100 %-2,363.87 %-2,321.17 %
2014100 %-3,410.31 %-3,289.14 %
201343.31 %-1,981.51 %-1,984.18 %
20123.84 %-518.57 %-527.86 %
20111.62 %-468.18 %-483.28 %
201074.2 %-13.81 %-5.41 %
200944.66 %-246.71 %-240.65 %
200850.27 %-455.76 %-636.73 %
2007100 %-1,100 %-1,068.79 %
2006100 %-1,957.78 %-1,981.11 %
2005100 %-610.36 %-585.76 %
2004100 %-197.96 %-192.42 %

Celldex Therapeutics Aktienanalyse

What does Celldex Therapeutics do?

Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Celldex Therapeutics's EBIT

Celldex Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Celldex Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Celldex Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Celldex Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Celldex Therapeutics stock

How much did Celldex Therapeutics achieve in EBIT for the current year?

In the current year, Celldex Therapeutics has achieved an EBIT of -185.31 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Celldex Therapeutics.

How has the EBIT of Celldex Therapeutics developed in recent years?

The EBIT of Celldex Therapeutics has increased by 30.458% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Celldex Therapeutics?

The EBIT of Celldex Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Celldex Therapeutics pay?

Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Celldex Therapeutics?

The current dividend yield of Celldex Therapeutics is .

When does Celldex Therapeutics pay dividends?

Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celldex Therapeutics?

Celldex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Celldex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celldex Therapeutics located?

Celldex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celldex Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Celldex Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Celldex Therapeutics in the year 2023?

In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.

In which currency does Celldex Therapeutics pay out the dividend?

The dividends of Celldex Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Celldex Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Celldex Therapeutics

Our stock analysis for Celldex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celldex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.